Literature DB >> 12601348

Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis.

Rosario F Velázquez1, Manuel Rodríguez, Carmen A Navascués, Antonio Linares, Ramón Pérez, Nieves G Sotorríos, Isabel Martínez, Luis Rodrigo.   

Abstract

Better knowledge of the risk factors associated with the appearance of hepatocellular carcinoma (HCC) could improve the efficacy of surveillance programs. A total of 463 patients aged 40 to 65 years with liver cirrhosis in Child-Pugh class A or B were included in a program of early diagnosis. The predictive value of different risk factors was evaluated using the Kaplan-Meier method and Cox regression model. Thirty-eight patients developed HCC. In the multivariate analysis, 4 variables showed an independent predictive value for the development of HCC: age 55 years or older, antibody to hepatitis C virus (anti-HCV) positivity, prothrombin activity 75% or less, and platelet count less than 75 x 10(3)/mm(3). According to the contribution of each of these factors to the final model, a score ranging between 0 and 4.71 points was constructed to allow the division of patients into 2 different risk groups. The low-risk group included those with a score of 2.33 points or less (n = 270; 4 with HCC; cumulative incidence of HCC at 4 years, 2.3%), and the high-risk group included those with a score greater than 2.33 (n = 193; 34 with HCC; cumulative incidence of HCC at 4 years, 30.1%) (P =.0001). In conclusion, a simple score made up of 4 clinical and biological variables allowed us to distinguish 2 groups of cirrhotic patients at high and low risk for the development of HCC. We believe this score can be useful in establishing a subset of cirrhotic patients in whom a surveillance program for early detection of HCC could be unjustified.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601348     DOI: 10.1053/jhep.2003.50093

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  114 in total

1.  Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy.

Authors:  Nikolaus Kohles; Dorothea Nagel; Dietrich Jüngst; Jürgen Durner; Petra Stieber; Stefan Holdenrieder
Journal:  Tumour Biol       Date:  2011-09-20

2.  Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States.

Authors:  Anne F Peery; Seth D Crockett; Alfred S Barritt; Evan S Dellon; Swathi Eluri; Lisa M Gangarosa; Elizabeth T Jensen; Jennifer L Lund; Sarina Pasricha; Thomas Runge; Monica Schmidt; Nicholas J Shaheen; Robert S Sandler
Journal:  Gastroenterology       Date:  2015-08-29       Impact factor: 22.682

3.  Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety.

Authors:  Y Nakamoto; E Mizukoshi; H Tsuji; Y Sakai; M Kitahara; K Arai; T Yamashita; K Yokoyama; N Mukaida; K Matsushima; O Matsui; S Kaneko
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

4.  Efficacy of ultrasonography and alpha-fetoprotein on early detection of hepatocellular carcinoma.

Authors:  Fen-Yu Ren; Xi-Xu Piao; Ai-Lian Jin
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

Review 5.  Hepatitis B virus-induced oncogenesis.

Authors:  Joachim Lupberger; Eberhard Hildt
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

6.  Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists.

Authors:  Pratima Sharma; Sameer D Saini; Latoya B Kuhn; Joel H Rubenstein; Darrell S Pardi; Jorge A Marrero; Philip S Schoenfeld
Journal:  Dig Dis Sci       Date:  2010-10-27       Impact factor: 3.199

Review 7.  Hepatocellular carcinoma: therapy and prevention.

Authors:  Hubert E Blum
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

8.  Initial experience of transcatheter arterial chemoembolization during portal vein occlusion for unresectable hepatocellular carcinoma with marked arterioportal shunts.

Authors:  Satoru Murata; Hiroyuki Tajima; Ken Nakazawa; Shiro Onozawa; Shinichiro Kumita; Kazuhiro Nomura
Journal:  Eur Radiol       Date:  2009-02-24       Impact factor: 5.315

9.  Screening for hepatocellular carcinoma by Egyptian physicians.

Authors:  Sahar M Hassany; Ehab F Abdou Moustafa; Mohamed El Taher; Afaf Adel Abdeltwab; Hubert E Blum
Journal:  World J Gastrointest Oncol       Date:  2015-09-15

10.  Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies.

Authors:  Robert D Mair; Antonia Valenzuela; Nghiem B Ha; Walid S Ayoub; Tami Daugherty; Glen A Lutchman; Gabriel Garcia; Aijaz Ahmed; Mindie H Nguyen
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-16       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.